ReviewCirculation2024
Unraveling the Mechanisms of Valvular Heart Disease to Identify Medical Therapy Targets: A Scientific Statement From the American Heart Association.
Review in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction.Nature genetics · 2026Pooled it
- Unimodal to multimodal: a systematic review of predictive machine learning models for valvular heart diseases.Frontiers in cardiovascular medicine · 2026Pooled it
- Bioactive 3D-Printed valve scaffold promoting valvular regeneration via immunomodulation and endothelialization.Bioactive materials · 2026Article
- Article
- Transcatheter Aortic Valve Replacement (TAVR) in Medicare Advantage and Medicare Fee-for-Service: Differences in Patient Characteristics, Utilization, and Outcomes.Circulation. Population health and outcomes · 2026Article
- Human iPSC-derived heart valve-like assembloids model valve development and disease pathology.Cell stem cell · 2026Article
- Association between the atherogenic index of plasma and outcomes in patients with severe aortic stenosis who undergo transcatheter aortic valve replacement.Chinese medical journal · 2026Article
- Immune Mechanisms of Heart Valve Development, Homeostasis, and Disease.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- A Continuum of Atrial Peristalsis Initiates the Bicuspid to Quadricuspid Valve Transition.bioRxiv : the preprint server for biology · 2026Article
- Imaging and biomarker-based risk stratification in TAVI: the role of epicardial fat, visceral fat, and adiponectin.European heart journal open · 2026Article
- Microplastics and Nanoplastics in Cardiovascular Disease: An Emerging Cardiovascular Risk Factor.Cardiovascular toxicology · 2026Review
- Article
- Assessment of Prevalence and Characteristics of Valvular Heart Disease: A Cross-Sectional Study From Yazd Health Study.Health science reports · 2026Article
- Calcific Aortopathy in Response to Aging and Injury.Circulation · 2026Review
- Considerations in the Use of Mouse Models of Vascular and Valvular Calcification.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Cell Calcification Models and Their Implications for Medicine and Biomaterial Research.Advanced healthcare materials · 2026Review
- Heightened propofol sensitivity and distinct electroencephalographic signatures in patients with valvular heart disease.BMC anesthesiology · 2026Observational
- Circulating serotonin is associated with calcific aortic valve stenosis: a two-phase metabolomics study.Frontiers in pharmacology · 2026Article
- Familial Hypocalciuric Hypercalcemia and Early Severe Aortic Stenosis in A Patient with two Different Heart Failure Episodes.European journal of case reports in internal medicine · 2026Article
- Integrated biomarker landscape for the early detection and management of calcific aortic valve disease.European journal of clinical investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Valvular heart disease is a common cause of morbidity and mortality worldwide and has no effective medical therapy. Severe disease is managed with valve replacement procedures, which entail high health care-related costs and postprocedural morbidity and mortality. Robust ongoing research programs have elucidated many important molecular pathways contributing to primary valvular heart disease. However, there remain several key challenges inherent in translating research on valvular heart disease to viable molecular targets that can progress through the clinical trials pathway and effectively prevent or modify the course of these common conditions. In this scientific statement, we review the basic cellular structures of the human heart valves and discuss how these structures change in primary valvular heart disease. We focus on the most common primary valvular heart diseases, including calcific aortic stenosis, bicuspid aortic valves, mitral valve prolapse, and rheumatic heart disease, and outline the fundamental molecular discoveries contributing to each. We further outline potential therapeutic molecular targets for primary valvular heart disease and discuss key knowledge gaps that might serve as future research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.